| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
182 |
| Employees |
16,900 |
| Revenues (TTM) (Millions $) |
4,422 |
| Net Income (TTM) (Millions $) |
-413 |
| Cash Flow (TTM) (Millions $) |
126 |
| Capital Exp. (TTM) (Millions $) |
300 |
Business Description
Catalent Inc. Overview
Catalent Inc. is a prominent global provider of advanced delivery technologies, development, and manufacturing solutions for a variety of healthcare products including pharmaceuticals, biologics, cell and gene therapies, and consumer health products. Founded in 2007 and headquartered in Somerset, New Jersey, the company has established a significant presence worldwide, operating over 35 facilities across North America, Europe, and the Asia-Pacific regions.
Core Services and Specialization
Catalent offers a comprehensive range of services centered around drug development and manufacturing, which include:
1. Drug Development: Catalent supports the drug development process from early-stage research to commercialization, focusing on optimizing formulations and improving clinical efficacy.
2. Clinical Trial Solutions: The company provides solutions to facilitate clinical trials, including the management and supply chain logistics necessary for global trials.
3. Analytical Testing: Catalent conducts extensive analytical testing services to ensure the quality and safety of products, which is crucial for regulatory compliance.
4. Drug Delivery Technologies: Catalent specializes in innovative delivery systems that enhance the bioavailability and performance of therapeutics, such as their proprietary delivery platforms that improve dosing precision and patient compliance.
5. Manufacturing Solutions: The company offers contract manufacturing services for a wide range of dosage forms including softgels, tablets, and injectable formulations, ensuring that products meet the high standards required by the industry.
Business Segments
Catalent operates through four distinct business segments:
1. Softgel and Oral Technologies: This segment focuses on the development and manufacture of a diverse array of solid and semi-solid dosage forms, particularly softgel capsules, which are known for their enhanced bioavailability and patient compliance.
2. Biologics: Catalents Biologics segment provides comprehensive services for gene therapy and biomanufacturing, offering expertise to biotechnology companies that develop complex biologic therapies.
3. Oral and Specialty Delivery: This segment is dedicated to the creation of advanced delivery technologies aimed at improving the effectiveness and stability of oral dosage forms. The OptiDose system developed by Catalent is a notable innovation, allowing for uniform granulation and efficient tablet compaction.
4. Clinical Supply Services: Catalent ensures that clinical trial supply chains function seamlessly, providing crucial support to facilitate the distribution and management of drugs during trials.
Commitment to Sustainability
Catalent is dedicated to sustainability and employs environmentally responsible practices across its operations. The company works with clients to integrate greener manufacturing processes, utilizing eco-friendly materials and technologies aimed at reducing energy use and minimizing waste. Catalent also engages in partnerships with academic institutions and industry leaders to promote improved health outcomes globally.
Conclusion
Catalent Inc. stands out as a key player in the pharmaceutical and biotechnology sectors, renowned for its advanced drug development and delivery systems. The company operates with a commitment to innovation, quality, and efficiency, helping clients ranging from large pharmaceutical firms to smaller biotech companies navigate the complexities of bringing life-changing treatments to market. With its global footprint and focus on sustainable practices, Catalent continues to shape the future of drug development and manufacturing.
Company Address: 14 Schoolhouse Road Somerset, 8873 NJ
Company Phone Number: 537-6200 Stock Exchange / Ticker: NYSE CTLT
|
%
0.4% 
100.1 %